Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: beta-lactamase stimulants - Synthetic Biologics

Drug Profile

Research programme: beta-lactamase stimulants - Synthetic Biologics

Alternative Names: P1B; P1C; P2A; P2B; P2C; P4A; SYN-006 - Synthetic Biologics

Latest Information Update: 18 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ipsat Therapies
  • Developer Synthetic Biologics
  • Class Enzymes
  • Mechanism of Action Beta lactamase stimulants; Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium difficile infections
  • Research Diarrhoea

Most Recent Events

  • 22 Mar 2017 Early research in Diarrhoea in USA (PO), before March 2017 (Synthetic Biologics Form10-K, March 2017)
  • 22 Mar 2017 Preclinical trials in Clostridium difficile infections (Prevention) in USA (PO) (Synthetic Biologics Form10-K, March 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Clostridium-difficile-infections(Prevention) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top